drugset / Trial / NCT05748600

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600

Phase 3 Active not recruiting 600 enrolled Areteia Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.

Timeline

Start
2023-01-30
Primary completion
2025-09
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexpramipexole Small molecule 75 mg Oral
Subject Dexpramipexole Small molecule 150 mg Oral

Indications